首页HDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
相关资讯
财务信息
损益表
收入
净收入
(USD) | 2024年3月info | 年同比变化 |
---|---|---|
收入 | — | — |
经营支出 | 1.26亿 | 28.63% |
净收入 | -1.25亿 | -357.42% |
净利润率 | — | — |
每股收益 | -1.02 | -326.67% |
息税折旧摊销前利润 | -1.22亿 | -339.34% |
有效税率 | — | — |
资产负债表
总资产
负债总额
(USD) | 2024年3月info | 年同比变化 |
---|---|---|
现金及短期投资 | 5.21亿 | 8.30% |
总资产 | 9.55亿 | 7.16% |
负债总额 | 4.60亿 | 7.87% |
权益总额 | 4.95亿 | — |
发行在外的股份 | 1.24亿 | — |
市净率 | 6.63 | — |
资产回报率 | -39.90% | — |
资本回报率 | -43.18% | — |
现金流
现金净变动
(USD) | 2024年3月info | 年同比变化 |
---|---|---|
净收入 | -1.25亿 | -357.42% |
来自运营的现金 | -9237.70万 | -191.68% |
投资现金 | -2.69亿 | -645.70% |
融资现金 | 4.31亿 | 82,741.73% |
现金净变动 | 6948.90万 | 203.27% |
自由现金流 | -9182.49万 | -262.49% |
简介
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
成立时间
2004年1月1日
员工数量
525